Optimizing Access to High-Quality, Standardized and Compliant Leukopaks for the Development and Commercialization of Allogeneic Therapies

Cellular starting material is the most critical component in the allogeneic cell therapy manufacturing process. Ensuring material access while maintaining quality, consistency and regulatory compliance are necessary throughout every stage of clinical development through commercialization.

During this webinar, you will learn about:

• Factors to ensure streamlined access to high-quality, consistent starting material for allogeneic therapies
• Key regulatory requirements for donor cellular starting material and how they vary between the US, EU and other regions/countries
• Automatically taking into account multiple donor features like age, gender, geographical location, race, ethnicity and more
• Attributes of a standardized leukopak for allogeneic cell therapy manufacturing

PRESENTER

Makensie Becker
Manager, Product Development
NMDP BioTherapies